222 related articles for article (PubMed ID: 15047606)
1. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle.
Arias EB; Kim J; Cartee GD
Diabetes; 2004 Apr; 53(4):921-30. PubMed ID: 15047606
[TBL] [Abstract][Full Text] [Related]
2. Relationship between protein O-linked glycosylation and insulin-stimulated glucose transport in rat skeletal muscle following calorie restriction or exposure to O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate.
Arias EB; Cartee GD
Acta Physiol Scand; 2005 Mar; 183(3):281-9. PubMed ID: 15743388
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes.
Park SY; Ryu J; Lee W
Exp Mol Med; 2005 Jun; 37(3):220-9. PubMed ID: 16000877
[TBL] [Abstract][Full Text] [Related]
4. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes.
Vosseller K; Wells L; Lane MD; Hart GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5313-8. PubMed ID: 11959983
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed proteins by treatment with PUGNAc in 3T3-L1 adipocytes through analysis of ATP-binding proteome.
Lee JE; Park JH; Moon PG; Baek MC
Proteomics; 2013 Oct; 13(20):2998-3012. PubMed ID: 23946262
[TBL] [Abstract][Full Text] [Related]
6. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate.
Haltiwanger RS; Grove K; Philipsberg GA
J Biol Chem; 1998 Feb; 273(6):3611-7. PubMed ID: 9452489
[TBL] [Abstract][Full Text] [Related]
7. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury.
Xing D; Feng W; Nöt LG; Miller AP; Zhang Y; Chen YF; Majid-Hassan E; Chatham JC; Oparil S
Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H335-42. PubMed ID: 18469144
[TBL] [Abstract][Full Text] [Related]
8. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells.
Matthews JA; Belof JL; Acevedo-Duncan M; Potter RL
Mol Cell Biochem; 2007 Apr; 298(1-2):109-23. PubMed ID: 17136481
[TBL] [Abstract][Full Text] [Related]
9. Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
Sermikli BP; Aydogdu G; Yilmaz E
Mol Biol Rep; 2020 Aug; 47(8):5927-5942. PubMed ID: 32691273
[TBL] [Abstract][Full Text] [Related]
10. Proteomics and PUGNAcity will overcome questioning of insulin resistance induction by nonselective inhibition of O-GlcNAcase.
Dehennaut V; Lefebvre T
Proteomics; 2013 Oct; 13(20):2944-6. PubMed ID: 23983178
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
[TBL] [Abstract][Full Text] [Related]
12. PUGNAc induces protein ubiquitination in C2C12 myotube cells.
Park JH; Lee JE; Moon PG; Baek MC
Cell Biochem Funct; 2015 Dec; 33(8):525-33. PubMed ID: 26531776
[TBL] [Abstract][Full Text] [Related]
13. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance.
Macauley MS; Bubb AK; Martinez-Fleites C; Davies GJ; Vocadlo DJ
J Biol Chem; 2008 Dec; 283(50):34687-95. PubMed ID: 18842583
[TBL] [Abstract][Full Text] [Related]
14. E. coli sabotages the in vivo production of O-linked β-N-acetylglucosamine-modified proteins.
Goodwin OY; Thomasson MS; Lin AJ; Sweeney MM; Macnaughtan MA
J Biotechnol; 2013 Dec; 168(4):315-23. PubMed ID: 24140293
[TBL] [Abstract][Full Text] [Related]
15. Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1.
Gandy JC; Rountree AE; Bijur GN
FEBS Lett; 2006 May; 580(13):3051-8. PubMed ID: 16684529
[TBL] [Abstract][Full Text] [Related]
16. PUGNAc treatment leads to an unusual accumulation of free oligosaccharides in CHO cells.
Mehdy A; Morelle W; Rosnoblet C; Legrand D; Lefebvre T; Duvet S; Foulquier F
J Biochem; 2012 Apr; 151(4):439-46. PubMed ID: 22337894
[TBL] [Abstract][Full Text] [Related]
17. The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels.
Zou L; Yang S; Hu S; Chaudry IH; Marchase RB; Chatham JC
Shock; 2007 Apr; 27(4):402-8. PubMed ID: 17414423
[TBL] [Abstract][Full Text] [Related]
18. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise.
Whitworth GE; Macauley MS; Stubbs KA; Dennis RJ; Taylor EJ; Davies GJ; Greig IR; Vocadlo DJ
J Am Chem Soc; 2007 Jan; 129(3):635-44. PubMed ID: 17227027
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcylation promotes non-amyloidogenic processing of amyloid-β protein precursor via inhibition of endocytosis from the plasma membrane.
Chun YS; Park Y; Oh HG; Kim TW; Yang HO; Park MK; Chung S
J Alzheimers Dis; 2015; 44(1):261-75. PubMed ID: 25208619
[TBL] [Abstract][Full Text] [Related]
20. Implications of the O-GlcNAc modification in the regulation of nuclear apoptosis in T cells.
Johnson B; Opimba M; Bernier J
Biochim Biophys Acta; 2014 Jan; 1840(1):191-8. PubMed ID: 24035784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
